These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 23116225)

  • 21. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
    Rosenbaum D; Girerd X
    Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.
    Weir MR; Hsueh WA; Nesbitt SD; Littlejohn TJ; Graff A; Shojaee A; Waverczak WF; Qian C; Jones CJ; Neutel JM
    J Clin Hypertens (Greenwich); 2011 Jun; 13(6):404-12. PubMed ID: 21649839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
    Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
    Tocci G; Paneni F; Passerini J; Volpe M
    Expert Opin Pharmacother; 2012 Dec; 13(18):2687-97. PubMed ID: 23170911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension.
    Deeks ED
    Drugs; 2011 Jan; 71(2):209-20. PubMed ID: 21275446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.
    Barrios V; Brommer P; Haag U; Calderón A; Escobar C
    Clin Drug Investig; 2009; 29(7):427-439. PubMed ID: 19499960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
    Ewald S; vor dem Esche J; Uen S; Neikes F; Vetter H; Mengden T
    Clin Drug Investig; 2006; 26(8):439-46. PubMed ID: 17163276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control.
    Parati G; Ochoa JE; Ramos C; Hoshide S; Lonati L; Bilo G
    Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):301-13. PubMed ID: 20921092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
    Nesbitt SD; Shojaee A; Maa JF; Weir MR
    J Hum Hypertens; 2013 Jul; 27(7):445-52. PubMed ID: 23254596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance.
    Rana R; Singh A
    J Assoc Physicians India; 2010 Feb; 58():77-83. PubMed ID: 20653147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
    Heagerty AM; Mallion JM
    Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.
    Barrios V; Escobar C; Calderon A; Böhm M
    Vasc Health Risk Manag; 2009; 5():723-9. PubMed ID: 19756164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
    Punzi HA
    Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
    Chrysant SG; Marbury TC; Silfani TN
    Blood Press Monit; 2006 Jun; 11(3):135-41. PubMed ID: 16702822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.
    Oparil S; Chrysant SG; Melino M; Lee J; Karki S; Heyrman R
    J Hum Hypertens; 2010 Dec; 24(12):831-8. PubMed ID: 20200547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.
    Kereiakes DJ; Chrysant SG; Izzo JL; Littlejohn T; Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
    J Clin Hypertens (Greenwich); 2012 Mar; 14(3):149-57. PubMed ID: 22372774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.
    Neutel JM; Kereiakes DJ; Waverczak WF; Stoakes KA; Xu J; Shojaee A
    Curr Med Res Opin; 2010 Mar; 26(3):721-8. PubMed ID: 20085534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olmesartan medoxomil: a review of its use in the management of hypertension.
    Scott LJ; McCormack PL
    Drugs; 2008; 68(9):1239-72. PubMed ID: 18547134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.